Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX77 Adagrasib
D12301 Adagrasib (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
KRAS Inhibitors
Adagrasib
D12301 Adagrasib (USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D12301 Adagrasib
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Environmental information processing
G protein
KRAS* [HSA_VAR:3845v1]
D12301 Adagrasib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12301
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D12301
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12301
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12301
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D12301